Edition:
United States

GlaxoSmithKline PLC (GSK.F)

GSK.F on Frankfurt Stock Exchange

16.52EUR
18 Aug 2017
Change (% chg)

€-0.33 (-1.96%)
Prev Close
€16.85
Open
€16.98
Day's High
€16.98
Day's Low
€16.52
Volume
14,717
Avg. Vol
30,047
52-wk High
€19.95
52-wk Low
€16.41

GSK.F

Chart for GSK.F

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)
No analyst recommendations are available for GSK.F.

Overall

No Ratios Available.

Financials

  GSK.F Industry Sector
P/E (TTM): -- 31.45 32.56
EPS (TTM): -- -- --
ROI: -- 15.33 14.89
ROE: -- 16.35 16.13

FDA panel votes against approval of J&J arthritis drug

The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 03 2017

FDA panel votes against approval of J&J arthritis drug

The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 02 2017

UPDATE 1-U.S. FDA panel votes against approval of J&J arthritis drug

Aug 2 The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 02 2017

J&J arthritis drug sirukumab raises safety concerns: FDA staff

There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.

Jul 31 2017

UPDATE 3-J&J arthritis drug sirukumab raises safety concerns -FDA staff

July 31 There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.

Jul 31 2017

GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs

LONDON GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business.

Jul 26 2017

REFILE-UPDATE 3-GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs

LONDON, July 26 GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business.

Jul 26 2017

GlaxoSmithKline's new boss streamlines drug research

LONDON, July 26 GlaxoSmithKline's new Chief Executive Emma Walmsley announced plans on Wednesday to streamline drug research in a bid to improve returns in the group's core pharmaceuticals business.

Jul 26 2017

BRIEF-ViiV announces positive results from DAWNING

* VIIV HEALTHCARE, MAJORITY OWNED BY GSK, WITH PFIZER AND SHIONOGI AS SHAREHOLDERS, ANNOUNCED POSITIVE INTERIM RESULTS FROM DAWNING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Jul 25 2017

BRIEF-GSK and Innoviva submit EU filing for extended use of Relvar Ellipta

* GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination Source text for Eikon: Further company coverage:

Jul 21 2017

Earnings vs. Estimates